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Abstract: Hyperphosphatemia has been shown to be involved not only in the onset and 
progression of secondary hyperparathyroidism but also in vascular calcification. In addition, it 
influences the clinical course of patients with chronic kidney disease. Phosphate (Pi) binder is 
required in the management of hyperparaphosphatemia, because dietary Pi restriction and Pi 
removal by hemodialysis alone are insufficient. Lanthanum carbonate, a powerful Pi binder, has 
a similar effect to aluminum hydroxide in reducing serum Pi levels. As it is excreted via the liver, 
lanthanum carbonate has an advantage in patients with renal failure. The effect of lanthanum 
carbonate on serum Pi levels is almost two times higher than that of calcium (Ca) carbonate, 
which is commonly used. Lanthanum carbonate and Ca carbonate have an additive effect. 
Worldwide, there is 6 years worth of clinical treatment data on lanthanum carbonate; however, 
we have 3 years of clinical use in Japanese patients with hyperphosphatemia. No serious side 
effects have been reported. However, the most important concern is bone toxicity, which has been 
observed with use of aluminum hydroxide. For this study, clinical research involved analysis of 
bone biopsies. Although osteomalacia is the most noticeable side effect, this was not observed. 
Both the high- and the low-turnover bone disease concentrated into a normal bone turnover state. 
However, as the authors have less than 10 years’ clinical experience with lanthanum carbonate, 
patients should be monitored carefully. In addition, it is necessary to demonstrate whether potent 
treatment effects on hyperphosphatemia improve the long-term outcome.
Keywords: phosphate binder, end-stage renal disease (ESRD), fibroblast growth factor 23 
(FGF23), vascular calcification
Introduction
In patients with chronic kidney disease (CKD), as renal function declines, hyper-
phosphatemia progresses with low urinary excretion of phosphate (Pi). Hyperphos-
phatemia has been shown to be an important factor in the onset and progression of 
secondary hyperparathyroidism. In a recent clinical study, hyperphosphatemia was 
shown to be a strong risk factor for cardiovascular events in patients with CKD,1 and 
hyperphoshatemia has also been known to cause vascular calcification.2 Because 
hyperphosphatemia is a significant mortality risk factor in patients with CKD,3,4 
the management of hyperphosphatemia is an important therapeutic target in CKD 
treatment.
Therapeutic strategy for hyperphosphatemia
Treatment for hyperphosphatemia in patients with CKD includes the following three 
modalities: diet therapy (ie, Pi restriction), hemodialysis (HD) (blood purification), and 
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pharmacological intervention. Although very effective, diet 
therapy can lead to malnutrition if continued for a long time, 
and dialysis therapy alone is not enough to effectively control 
hyperphosphatemia, with Pi removal of only 2400 mg/week in 
CAPD patients and 3000 mg/week in HD patients with 3 times 
a week sessions (Figure 1). Accordingly, pharmacological 
therapy (Pi binder prescription) is an inevitable option.
Although many Pi binders have been used in clinical 
practice, there is no ideal Pi binder as yet available. Criteria 
for an ideal Pi binder include (1) good compliance (easy to 
take the drug); (2) powerful reducing power of serum Pi; 
(3) no evidence of accumulation; and (4) no serious side 
effects. In 1992, the powerful Pi binder aluminum hydroxide 
was contraindicated in uremic patients in Japan because of its 
bone and central nervous system (CNS) toxicity.5 Since then, 
calcium (Ca)-containing Pi binders have been prescribed 
widely, although they have hypercalcemia as a major adverse 
effect. However, aluminum hydroxide is still used as a Pi 
binder in European countries and it is also used, albeit on a 
limited basis, in the United States (US).
As a non-Ca/non-aluminum Pi binder, a synthetic polymer 
of sevelamer hydrochloride has gradually been applied in 
clinical practice. The sevelamer hydrochloride can work 
not only as a non-Ca, non-aluminum Pi binder but also as 
an effective inhibitor for vascular calcification. Chertow 
et al6 have clearly shown the inhibitory effect on coronary 
and aortic calcification of sevelamer with reduction of CaPi 
product. However, side effects in the digestive system such as 
constipation have caused low compliance in Japanese dialyzed 
patients. In addition, sevelamer hydrochloride exacerbates 
metabolic acidosis due to the release of chloride ions in the 
intestinal cavity.7 The next sevelamer without deterioration 
of metabolic acidosis is sevelamer carbonate, and this may 
be better for CKD patients with hyperphosphatemia prior to 
dialysis therapy.8 Unfortunately, sevelamer carbonate has not 
been developed in the Japanese market as another non-Ca/non-
aluminum Pi binder, and it is still not available in Japan.
Lanthanum carbonate was finally approved in Japan as a 
Pi binder for use in patients on dialysis in March 2009. This 
product was developed as a chewable tablet able to be taken 
without water, making it suitable for dialyzed patients. This 
article will discuss the novel Pi binder with a particular focus 
on lanthanum carbonate.
Lanthanum carbonate therapy  
for hyperphosphatemia
Chemical structure and pharmacological 
action of lanthanum carbonate
Lanthanum is a trivalent rare earth element with an atomic 
number of 57. The molecular formula of lanthanum carbonate 
is La2(CO3)3 ⋅ 4H2O and the drug molecular weight is 529.9. 
After oral administration, lanthanum carbonate creates a strong 
insoluble bond with Pi and is excreted in the feces. In vitro 
studies, more than 97% of added phosphorus (pH 3 and pH 5) 
was removed and, similarly to aluminum hydroxide, lan-
thanum carbonate demonstrated better absorption than Ca 
carbonate.9 Lanthanum carbonate is water insoluble, and 
its intestinal absorption is extremely low, between 0.0007% 
(rats) and 0.00005% (dogs). Results showed 99.4% of the oral 
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Figure 1 Results of weekly phosphate (Pi) removal by hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) procedures. The amount of Pi removed 
weekly by HD sessions three times a week was 2388–3006 mg/week in eleven patients. The removal by CAPD with residual kidney function was 2300 ± 113 mg/week in 
13 patients, less than that by HD. These amounts of Pi removed by conventional dialysis therapy alone are insufficient, and this is why a Pi binder is used.
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lanthanum carbonate dose was recovered in the feces. When 
lanthanum chloride was intravenously administered to rats, 
96.9% of lanthanum was recovered in the feces. Accordingly, 
the major excretion route for lanthanum is via the bile, which 
is an advantage for patients with renal failure.10 In Europe, 
this product was approved as a Pi binder in Sweden in March 
2004. It was approved in the US in April 2005, and Japanese 
approval was granted in April 2009. Since then, the product 
has been used in clinical settings.
Phosphorus-reduction effect  
of lanthanum carbonate
The therapeutic effect of lanthanum carbonate for hyperphos-
phatemia has been demonstrated in several clinical studies.9,11 
Joy et al11 reported more significant effect on hyperphos-
phatemia with lanthanum carbonate than with Ca carbonate 
through a randomized, double-blind study in HD patients. This 
study consisted of a washout period for premedication with 
Ca products (1–3 weeks); a 6-week dose adjustment period 
(the initial dose of lanthanum carbonate was 750 mg/day and 
was increased to a maximum of 3000 mg/day); and a 4-week, 
fixed-dose, double-blind period (comparison between Ca car-
bonate and lanthanum carbonate groups). During the course 
of the study, the serum Pi level in the lanthanum carbonate 
group (n = 49) was 7.69 mg/dL in the washout period and 
5.49 ± 1.48 mg/dL in the dose adjustment period; at comple-
tion of the double-blind study period, it was 5.94 ± 1.65 mg/dL 
and was thus controlled at below 6.0 mg/dL. On the other 
hand, in the comparator group (n = 44), serum Pi level 
before and after the double-blind period increased from 
5.62 ± 1.61 mg/dL to 7.85 ± 1.96 mg/dL. The serum Pi level 
in the comparator group was significantly higher than that in 
the lanthanum carbonate group.
In Japan, the authors reported the serum Pi control effect 
of lanthanum carbonate in a randomized, double-blind, 
placebo-controlled, multicenter, dose-dependent study in 
HD patients.12 After a 3-week washout period, patients were 
randomly allocated either to a placebo group or to lanthanum 
carbonate groups (four groups: 750 mg/day, 1500 mg/day, 
2250 mg/day, and 3000 mg/day) and a 6-week observation 
period was provided. Serum concentrations of Pi were reduced 
in a dose-dependent manner up to 2250 mg/day of lantha-
num carbonate and its effect was observed within 1 week 
after initiation of oral lanthanum carbonate administration 
(Figure 2). Serum Ca was not significantly changed during 
the whole treatment period. As a result, it was concluded 
that the therapeutic dose range suitable for HD patients with 
hyperphosphatemia is 1500–2250 mg/day, and 750 mg/day is 
recommended as the initial dose.12 In addition, the treatment 
effect of lanthanum carbonate on hyperphosphatemia in con-
tinuous ambulatory peritoneal dialysis patients was reported. 
In this patient population, 750–1500 mg/day or a smaller dose 
range than in HD patients is considered optimal.13 Successful 
treatment for hyperphosphatemia can achieve the reduction 
of CaPi product. As one of the risk factors for vascular calci-
fication, this CaPi product is mainly determined by serum Pi 
level, but not by Ca level (Figure 3A and B).14 The lanthanum 
carbonate without Ca as a Pi binder may inhibit vascular 
−3 −2 −10 1
(Weeks)
S
e
r
u
m
 
P
 
(
m
g
/
d
L
)
1
2
3
4
5
6
7
8
9
10
23 456
Endpoint
1500 mg/day (N = 23~28)
2250 mg/day (N = 24~31)
3000 mg/day (N = 15~31)
Placebo (N = 19~31)
(Mean ± SD)
750 mg/day (N = 27~30)
Figure 2 Lanthanum carbonate effectively controls serum phosphate (Pi) in a dose-dependent manner. The result was obtained from the prospective, randomized, double-
blind, placebo-controlled, multicenter study on Japanese hemodialysis patients. Changes in serum Pi level from week −3 to week 6 are presented for each treatment group, 
together with the last observation carried forward as the endpoint. Lanthanum carbonate effectively controls serum Pi without affecting serum calcium level. The magnitude 
of serum Pi level reduction is greater at higher dosages, but it reached a plateau at a daily dose of 2250 mg.
Note: Copyright © 2011. Reproduced with permission from John Wiley and Sons. Shigematsu T; for Lanthanum Carbonate Research Group. Lanthanum carbonate 
effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2008;12(1):55–61.12
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calcification in CKD patients. Further prospective interven-
tional study is required to prove this inhibitory effect.
One study of lanthanum carbonate treatment was per-
formed for comparison with Ca carbonate or sevelamer 
hydrochloride.15 In this double-blind, comparative study with 
Ca carbonate, the serum Pi level was well controlled in both 
the lanthanum carbonate group and the Ca carbonate group 
during the 8-week treatment period.15 The therapeutic effect 
was almost the same. It was concluded that since lanthanum 
carbonate is not associated with hypercalcemia, it is advanta-
geous for patients on HD (Figure 4A and B). The dosage of 
lanthanum carbonate was approximately half that of the Ca 
carbonate dosage (Figure 4C). The treatment effect on hyper-
phosphatemia was approximately two times greater with 
lanthanum carbonate than with Ca carbonate. In addition, in 
a randomized, crossover study with sevelamer hydrochloride, 
the Pi level was reduced in both groups and in the intention-
to-treat analysis. There was no significant difference in the 
serum Pi at 4 weeks between the two groups.16
Recent studies in Europe17,18 and the US19,20 have inves-
tigated long-term treatment with lanthanum carbonate over 
6 years. According to these studies, the decreased serum 
Pi level and CaPi products were maintained during the 
observation period. After 6 years, serum Pi level was main-
tained within a range of 4.5–6.5 mg/dL and there were no 
significant side effects known.18 In Japan, the authors have 
reported results of 3 years of long-term lanthanum carbonate 
treatment.21 Serum Pi level and CaPi product were reliably 
maintained for 3 years and treatment was continued without 
significant side effects (Figure 5A and B). However, the dose 
reduction of Ca carbonate prescription may induce elevation 
of the parathyroid hormone (PTH) (Figure 5C). This PTH 
elevation should be monitored carefully for a long time.
Safety and side effects of lanthanum 
carbonate
Lanthanum carbonate is a metallic salt that is not metabo-
lized in vivo. Accordingly, there is concern about in vivo 
accumulation, as with aluminum products. A lot of evidence, 
including from animal and clinical studies, has been accumu-
lated on this point. In a comparative study with Ca carbon-
ate in patients with renal osteodystrophy on HD,22 a bone 
biopsy was conducted before and 1 year after treatment. 
There was no progression to osteomalacia or adynamic 
bone disease observed in the lanthanum carbonate group, 
unlike in cases with aluminum hydroxide. In the same study, 
histomorphometric parameters of bone turnover focused on 
basically normal bone turnover. Malluche et al23 reported 
bone biopsy and bone mineral density results in a randomized 
comparative study with a conventional Pi binder before and 
after 1 and 2 years of lanthanum treatment. From this study, 
there was no significant difference between the two groups 
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Figure 3 Correlation between the calcium (Ca)-phosphate (Pi) product and the serum Ca or serum Pi concentration. The serum Pi level was the significant factor in 
determining CaPi product. The CaPi product is mainly determined by the Pi concentration and is closely correlated with the serum Pi (Y = 10.476 − 5.155, r2 = 0.914), but 
not with the serum Ca (r2 = 0.229). 
Note: Reproduced from Shigematsu T, Kono T, Satoh K, et al. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial 
Transplant. 2003;18 Suppl 3:iii86–iii89,14 with permission from Oxford University Press.
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Figure  4  Prospective,  randomized,  double-blind,  multicenter  comparative  study 
between lanthanum carbonate and calcium (Ca) carbonate as phosphate (Pi) binder 
in hemodialysis patients with hyperphosphatemia. In the lanthanum carbonate group, 
the mean serum Pi level decreased from 8.35 mg/dL at baseline to 5.78 mg/dL at 
week 5, and the serum Pi level was maintained up to the last visit. (A) A similar 
decrease in serum Pi level was also observed in the Ca carbonate group. During 
the double-blind period, the corrected serum Ca levels in the Ca carbonate group 
gradually increased, while those in the lanthanum carbonate group were relatively 
constant. (B) The daily doses of lanthanum carbonate became relatively constant 
during the last 4 weeks. At the last visit, the daily doses of lanthanum carbonate and 
Ca carbonate were 1725.7 and 3430.4 mg/day, respectively (C).
Note:  Reproduced  from  Shigematsu T;  Lanthanum  Carbonate  Research  Group. 
Multicenter  prospective  randomized,  double-blind  comparative  study  between 
lanthanum  carbonate  and  calcium  carbonate  as  phosphate  binders  in  Japanese 
hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70(5):404–410,15 
with permission from Dustri-verlag Dr Karl Feistle GmbH and Co KG.
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at 1 year. However, at 2 years, the lanthanum carbonate group 
was significantly improved in bone density compared with 
the conventional Pi binder group. In Japan, the authors also 
reported the results of a biopsy after 3 years of lanthanum 
carbonate treatment. In high-turnover bone disease, the bone 
turnover was returned. On the other hand, the bone turnover 
was stimulated in patients with low-turnover bone disease. 
Therefore, bone turnover was concentrating into a normal 
bone turnover state (Figure 6).24
Lanthanum carbonate did not show toxicity on osteoblast 
in animal bone biopsy experiments using renal failure rats. 
However, whether there are adverse effects in humans is still 
to be determined.25 Next, as CNS toxicity has also been a 
concern with aluminum as a Pi binder, a randomized study 
to evaluate the effects of lanthanum carbonate on cognitive 
function in comparison with the standard treatment in HD 
patients was achieved. After 2 years of observation, the 
decline of cognitive function with lanthanum carbonate was 
comparable with the standard treatment. No evidence of CNS 
toxicity was demonstrated.26 In addition, since lanthanum 
carbonate is excreted via bile, accumulation in the liver 
and hepatotoxicity, which are not observed with aluminum 
products, were investigated. Slatopolsky et al27 reported that 
lanthanum accumulated in the liver in a study using renal 
failure rats. In subsequent investigations, as lanthanum was 
a locally present lysosome in the liver and was excreted via 
bile, no hepatotoxicity was observed.28,29 In addition, there 
was no liver toxicity in HD patients treated with lanthanum 
carbonate for 6 years’ long-term follow-up.18
Other effects of lanthanum carbonate
Orally disintegrating lanthanum carbonate tablets have good 
adherence in patients through powerful hyperphosphatemia 
control activity similar to that of aluminum hydroxide, the 
most powerful Pi binder. There are several other noteworthy 
effects of lanthanum carbonate.
Medical economic effects
The use of aluminum hydroxide is prohibited in Japan for 
patients under dialysis therapy. Therefore, the effect of lan-
thanum carbonate in reducing the Pi level is the strongest 
when compared with other Pi binders. The favorable medical 
economic effects of lanthanum carbonate have been reported 
in second-line therapy for hyperphosphatemia as a risk factor 
for patient mortality, using quality-adjusted life years as a 
novel parameter.30
The reduction effect of serum fibroblast  
growth factor 23
In HD patients, high serum concentrations of fibroblast 
growth factor 23 (FGF23) are reported as an independent risk 
factor for patient mortality.31 Serum FGF23 is reduced inde-
pendent of PTH by the concomitant therapy with lanthanum 
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Figure 5 Clinical effects of 3-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. (A) The mean serum phosphate (Pi) level was 
8.03 ± 1.51 mg/dL at baseline, and it decreased to 5.33 ± 1.27 mg/dL and 5.33 ± 1.04 mg/dL after 1 year and 3 years of treatment, respectively. The mean reduction of Pi from 
baseline was within the range of −1.51 ± 1.48 mg/dL in week 1 (95% CI: −1.76, −1.27) to −3.08 ± 1.76 mg/dL in week 128 (95% CI: −3.69, −2.47). (B) The calcium (Ca)-Pi 
product has been well controlled below 55.0 (mg/dL)2 dependent on serum Pi level. (C) On the other hand, the intact parathyroid hormone (PTH) level was elevated overall 
and then stable throughout the treatment period, with a median value of 262.0 pg/mL at baseline and 283.8 pg/mL at 3 years.
Note: From Shigematsu21 with permission from Springer Japan and the Japanese Society of Nephrology.
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Figure 6 Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. In seven patients, pretreatment diagnosis was a fibrous 
osteitis–type disorder in two patients, a milder-type disorder in three patients, and an adynamic bone disease (ABD)–type disorder in two patients. After 1 year of treatment, 
the diagnosis changed to a milder-type disorder in all seven patients. After 3 years of treatment, bone biopsy was conducted on a total of four patients. The diagnosis of a 
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the osteoid condition toward normalization both in cases of excessive and cases of insufficient osteoid, and that the treatment also improved the resorption condition toward 
normalization in cases with both enhanced and reduced resorption.
Note: Copyright © 2011. Reproduced with permission from John Wiley and Sons. Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H. Effect of lanthanum carbonate 
treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial. 2011;15(2):176–184.24
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Figure 7 Combined therapy with lanthanum carbonate and calcium (Ca) carbonate for hyperphosphatemia decreases serum FGF23 levels independently of Ca and parathyroid 
hormone (PTH). The horizontal bar in each box indicates the median value. Upper and lower borders of the box are the 25th and 75th percentiles, respectively. Maximum and 
minimum values are shown by the vertical error bars. The significant 40% reduction of the circulating intact FGF23 level from baseline was observed after week 8 and week 16 
of combined therapy of lanthanum carbonate and Ca carbonate therapy. On the other hand, the intact PTH level did not show any significant change within 16 weeks.
Note: Reproduced from Shigematsu T, Negi S; for the COLC Research Group. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia 
decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant. 2012;27(3):1050–1054,32 with permission from Oxford Journals.
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carbonate and Ca carbonate for hyperphosphatemia in HD 
patients (Figure 7A and B).32 In this study, the baseline 
FGF23 level was 8250 (115–40200) ng/L. It showed a signifi-
cant decrease after week 8 and week 16 of add-on lanthanum 
carbonate therapy, decreasing to 5200 (38–31400) ng/L and 
5000 (78–30700) ng/L, respectively. The authors measured 
intact FGF23 with a Kainos Laboratories assay kit (Kainos 
Laboratories, Inc, Tokyo, Japan), so the observed reduction 
of serum FGF23 levels was thought to directly reflect a reduc-
tion of FGF23 production in the bone. On the other hand, the 
baseline intact PTH was 134.7 (12.0–379.3) pg/mL, and it 
also showed no significant change during add-on lanthanum 
carbonate therapy. A significant correlation between reduc-
tion of the serum Pi and the change of serum FGF23 level 
was observed. As the reduction of serum Pi became more 
marked, the decrease of serum FGF23 also became greater 
(Figure 7C).32
Similar PTH-independent reduction of FGF23 by 
lanthanum carbonate has also been reported in CKD patients 
without HD therapy.33 The significant decrease of serum 
Pi level induced the reduction of serum FGF23. However, 
the clinical effect of this phenomenon is still unknown. 
A prospective, randomized, placebo-controlled study is 
required to answer this question.
Precautions in X-ray examinations
Lanthanum carbonate contains lanthanum, a typical lan-
thanide. Accordingly, it is detected as a contrast image 
in X-ray examinations. If tablets are swallowed, they are 
recognized as small disc shapes. When tablets are well 
chewed, they are quite often shown as contrast shadows in 
the stomach and intestinal tract. They are seen as clear con-
trast images in computerized tomography and dual energy 
X-ray absorptiometry scanning.34,35 The administration of 
lanthanum carbonate should be prohibited prior to X-ray 
imaging procedures.
Therapeutic effect on calciphylaxis
Calciphylaxis is a pathological illness of severe arteriolar 
calcification with internal occlusion and necrosis. The progno-
sis of this disease is poor. It has been reported that lanthanum 
carbonate was aggressively used for calciphylaxis in a patient 
with acute kidney injury, saving the life of the patient.31
Inhibitory effect on vascular calcification
Hyperphosphatemia is a risk factor for the progression 
of vascular calcification.2,14,37 It has been reported that 
the beneficial effect of lanthanum carbonate therapy for 
hyperphosphatemia may suppress vascular calcification. 
Toussaint et al38 reported that lanthanum carbonate was 
associated with reduced progression of aortic calcification 
compared with calcium carbonate in 30 HD patients over 
18 months. This interesting result should be observed by a 
prospective, large-scale, long-term clinical study. At present, 
a prospective, large-scale observational study (STudy 
Of hyperPhosphatemia in CKD5D patients undergoing 
HemoDialysis [STOP-HD trial]: UMIN-ID 000002002) 
to confirm the inhibitory effect of lanthanum carbonate on 
vascular calcification is progressing in Japan. Results of the 
study are awaited.
Conclusion
Hyperphosphatemia is an important complication and it 
may affect the prognosis of CKD patients. At present, many 
Pi-reduction drugs are under development. Lanthanum 
carbonate, a new class of non-Ca/non-aluminum Pi binder, 
shows potent effects in hyperphosphatemia management. No 
report as yet suggests real toxicity for bone and the CNS, which 
have caused concern. Clinical use of this compound will be 
explored. However, observations reported so far are short-term 
and none of them cover a period of more than 10 years. Thus, 
it appears that further detailed investigations are needed.
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